| Literature DB >> 27585553 |
Zhi-Jun Li1, Yao Wang2, Gui-Jun Xu3, Peng Tian3.
Abstract
BACKGROUND: This meta-analysis was performed to identify the benefits and disadvantages of the PEEK cage and titanium cage.Entities:
Keywords: Cage; Cervical spine; Meta-analysis; Polyetheretherketone; Titanium
Mesh:
Substances:
Year: 2016 PMID: 27585553 PMCID: PMC5009677 DOI: 10.1186/s12891-016-1234-1
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1PRISMA flowchart of studies
Characteristics of included studies
| study | group | Gender (M/F) | Age(Y) | Segments (one/two/three) | Diseases(T/P) | Cage information | Follow-up(m) |
|---|---|---|---|---|---|---|---|
| Chou YC et al. 2008 [ | TTN | 11/16 | 55.2 | 43(14/10/3) | Trauma(1/2) | Non-threaded cage containing a biphasic calcium phosphate ceramic | 12 |
| PEEK | 6/3 | 54.2 | 15(3/6/0) | containing a biphasic calcium phosphate ceramic | 12 | ||
| Niu CC et al. 2010 [ | TTN | 15/13 | 49.5 ± 11.3 | 37(19/9/0) | Radiculopathy(21/9) | hydroxyapatite-coated, box-shaped device with a tooth-threaded surface filled with a local bone graft and a calcium phosphate bone substitute | 31.9 ± 3.4 |
| PEEK | 12/13 | 52.2 ± 10.5 | 34(16/9/0) | filled with allo-cancellous bone graft | 30.4 ± 3.3 | ||
| Cabraja M et al. 2012 [ | TTN | 26/18 | 51.1 ± 8.9 | 44(1/0/0) | Radiculopathy(36/34) | with Plasmapore coating | 30.6 ± 14.3 |
| PEEK | 28/14 | 57.6 ± 11.1 | 42(1/0/0) | N | 26.1 ± 10.0 | ||
| Chen Y et al. 2013 [ | TTN | 17/12 | 45.7 ± 7.2 | 87(0/0/3) | Radiculopathy(16/18) | N | 97.2 |
| PEEK | 16/15 | 47.2 ± 6.8 | 93(0/0/3) | N | 102.1 |
Notes: TTN, Titanium, PEEK polyetheretherketone, OPLL ossification of the posterior longitudinal ligament, HIVD herniated intervertebral disc, N non-mentioned
Details about methodological quality of included studies
| Quality assessment for randomized trials | Niu CC | Chen Y | Chou YC | Cabraja M | Quality assessment for non-randomized trials |
|---|---|---|---|---|---|
| Was the assigned treatment adequately concealed prior to allocation? | 2 | 1 | 2 | 2 | A clearly stated aim |
| Were the outcomes of participants who withdrew described and included in the analysis? | 0 | 2 | 1 | 1 | Inclusion of consecutive patients |
| Were the outcome assessors blinded to treatment status? | 2 | 0 | 0 | 0 | Prospective data collection |
| Were the treatment and control group comparable at entry? | 2 | 2 | 1 | 2 | Endpoints appropriate to the aim of the study |
| Were the participants blind to assignment status after allocation? | 0 | 0 | 1 | 2 | Unbiased assessment of the study endpoint |
| Were the treatment providers blind to assignment status? | 0 | 0 | 2 | 2 | A follow-up period appropriate to the aims of the study |
| Were care programmes, other than the trial options, identical? | 2 | 2 | 2 | 2 | Less than 5 % loss to follow-up |
| Were the inclusion and exclusion criteria clearly defined? | 2 | 2 | 0 | 0 | Prospective calculation of the sample size |
| Were the interventions clearly defined? | 2 | 2 | 2 | 2 | Prospective calculation of the sample size |
| Were the outcome measures used clearly defined? | 2 | 2 | 1 | 2 | An adequate control group |
| Were diagnostic tests used in outcome assessment clinically useful? | 2 | 2 | 2 | 1 | Baseline equivalence of groups |
| Was the surveillance active, and of clinically appropriate duration? | 2 | 2 | 2 | 2 | Adequate statistical analyses |
Fig. 2Forest plot showing clinical functional status by Odom criteria
Fig. 3Forest plot showing fusion rate between two groups
Fig. 4Forest plot showing subsidence between two groups
Fig. 5Forest plot showing the final segmental angle between two groups